General Psychiatry - Articles - Page 96

The Brain May Remove Toxins During Sleep

October 1, 2013

Scientists have discovered that the brains of mice clean toxins from between cells while they are sleeping. During sleep, the space between brain cells increases by about 60%, allowing the glymphatic system, or the brain’s “plumbing” system, to flush the brain with fluid.

Learning Objectives, Treatment of Dementia, TCPR, October 2013

October 1, 2013

After reading these articles, you should be able to…

Antipsychotics and Anticonvulsants for Anxiety Disorders

September 1, 2013

Steve Balt, MD, MS

Steve Balt, MD, MS Board Member, The Carlat Report. In private practice in the San Francisco Bay area. Dr. Balt discloses that his spouse is employed as a sales representative for Otsuka America.

We know how frequently our patients complain of anxiety. Anxiety disorders are common, chronic conditions. They also increase the risk for mood and substance disorders, and complaints of anxiety are found in a wide range of other psychiatric and medical conditions, as well.

Table - FDA Approved Medications for Anxiety

September 1, 2013

Steve Balt, MD, MS

Steve Balt, MD, MS Board Member, The Carlat Report. In private practice in the San Francisco Bay area. Dr. Balt discloses that his spouse is employed as a sales representative for Otsuka America.

Documents: FDA-Approved Medications for Anxiety.pdf...

EXPERT Q&A

Anxiety Disorders in DSM-5 and Beyond

September 1, 2013

Daniel Pine, MD

Daniel Pine, MD

Chief, Section on Development and Affective Neuroscience, National Institute of Mental Health, Chair, DSM-5 Work Group on Child and Adolescent Psychiatric Disorders Dr. Pine has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Dr Daniel Pine, chief of the section on Development and Affective Neuroscience at the NIMH and chair of the DSM-5 Work Group on Child and Adolescent Psychiatric Disorders discusses anxiety disorders in the current and future state of anxiety disorder research and practice.

RESEARCH UPDATE

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

September 1, 2013

Glen Spielmans, PhD

Section editor, Glen Spielmans, PhD

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

What’s the optimal treatment for a first episode of psychosis? Few would argue against antipsychotic treatment, but what happens when the patient achieves remission?

NEWS OF NOTE

Fetzima Approved for Depression

September 1, 2013

In July 2013, the FDA approved the SNRI Fetzima (levomilnacipran) for major depressive disorder (MDD) in adults (Forest Laboratories, Inc). The efficacy of Fetzima at doses 40 mg to 120 mg once daily was established in three, eight-week, randomized, double-blind, placebo-controlled studies in adults diagnosed MDD.

Learning Objectives, Anxiety Disorders, TCPR, September 2013

September 1, 2013

After reading these articles, you should be able to…

OTC Agents for Depression, Anxiety, and Insomnia

July 1, 2013

Cara Hoepner, NP

Cara Hoepner, NP psychiatric nurse practitioner and Clinical Specialist, San Francisco, CA Ms. Hoepner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

More than 38% of Americans use complementary and alternative medicine (CAM) yearly, with 12.7% using so-called “natural products." More than a third of people over age 50 report use of supplements, yet only about half have discussed this with their doctors.

Nootropics and Antioxidants: The Next Big Things in Psychiatry?

July 1, 2013

Emily Deans, MD

Emily Deans, MD Clinical Instructor, Harvard Medical School Dr. Deans has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With an ongoing desire for “natural” products, and disappointment with the cost and efficacy of current prescription medications, more patients have turned to supplements. As a psychiatrist, the more you know about these supplements, the better you can have a conversation about their known risks and benefits.

General Psychiatry
RSS

The Brain May Remove Toxins During Sleep

Learning Objectives, Treatment of Dementia, TCPR, October 2013

Antipsychotics and Anticonvulsants for Anxiety Disorders

Table - FDA Approved Medications for Anxiety

Anxiety Disorders in DSM-5 and Beyond

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

Fetzima Approved for Depression

Learning Objectives, Anxiety Disorders, TCPR, September 2013

OTC Agents for Depression, Anxiety, and Insomnia

Nootropics and Antioxidants: The Next Big Things in Psychiatry?

Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

Psychopharm Secrets: What Patients Won’t Tell You

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry RSS

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry
RSS